Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

It acts by numerous mechanisms, like augmented insulin secretion (glucose-dependent), inhibition of glucagon release and suppressed hepatic gluconeogenesis, thereby reducing both fasting and ...

[20] recently demonstrated that hepatic insulin action is normal ... [30], thereby reducing rates of gluconeogenesis [31], and through reduction of plasma glucagon levels by inhibition of its ...

Insulin allows cells to absorb and use glucose. In people with insulin resistance, the cells are unable to use insulin effectively. Insulin resistance occurs when cells in the body do not respond ...

CCK denotes cholecystokinin, GI gastrointestinal, GLP-1 glucagon-like peptide 1, and PYY peptide YY. Hunger is controlled by redundant neuroendocrine circuitries that maintain metabolic balance.

Metabolic disorders such as iron overload, glycolysis, insulin resistance, lipid dysregulation, and glutaminolysis are found to induce liver senescence and ferroptosis, which are hot topics in the ...